4D Molecular Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FDMT research report →
Range $20 – $37
Price Chart
About the company
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders).
- CEO
- David H. Kirn
- IPO
- 2020
- Employees
- 196
- HQ
- EmeryVille, CA, US
Get TickerSpark's AI analysis on FDMT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $576.76M
- P/E
- -3.87
- PEG
- -0.20
- P/S
- 6.21
- P/B
- 2.31
- EV/EBITDA
- -2.89
- Div Yield
- 0.00%
- Gross Margin
- 91.54%
- Op Margin
- -226.05%
- Net Margin
- -208.57%
- ROE
- -47.06%
- ROIC
- -56.89%
Latest fiscal year · YoY change
- Revenue
- $85.21M+230194.6%
- Gross Profit
- $77.58M+154.9%
- Op Income
- $-159,547,000
- Net Income
- $-140,109,000+12.9%
- EPS
- $-2.42+18.8%
- OCF Growth
- +18.9%
- FCF Growth
- +20.8%
- 52W High
- $16.93
- 52W Low
- $6.96
- 50D MA
- $12.86
- 200D MA
- $11.11
- Beta
- 2.91
- RSI (14)
- 37
- Avg Volume
- 970.56K
No earnings-call transcripts are available for FDMT yet.
- Free Float
- 79.1%
- Shares Outstanding
- 55.24M
- Float Shares
- 43.69M
of shares held by institutions
166 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jupiter Topco LLC | 5.75M | ▲ 5.75M |
| Janus Henderson Group Ltd. | 5.73M | ▲ 5.73M |
| Ra Capital Management, L.P. | 5.05M | 0 |
| Blackrock, Inc. | 4.72M | ▲ 178.84K |
| Goldman Sachs Group Inc | 3.93M | ▼ 328.26K |
| Vanguard Group Inc | 3.09M | ▲ 518.40K |
| Novo Holdings A/S | 3.00M | ▼ 249.18K |
| Bvf Inc/Il | 2.88M | 0 |
| State Street Corp | 2.47M | ▼ 441.68K |
| Adage Capital Partners Gp, L.L.C. | 2.29M | ▲ 40.00K |
| T. Rowe Price Investment Management, Inc. | 2.27M | ▼ 245.85K |
| Trails Edge Capital Partners, LP | 2.23M | 0 |
Held by 220 ETFs
Biggest fund positions in FDMT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 16, 26 | Bizily Scott | other | 1,635 |
| Oct 16, 26 | Bizily Scott | other | 1,635 |
| Oct 16, 26 | Bizily Scott | sell | 1,635 |
| Oct 5, 26 | Kirn David | sell | 58,061 |
| Oct 5, 26 | Kirn David | sell | 272 |
| Sep 16, 26 | Bizily Scott | other | 1,635 |
| Sep 16, 26 | Bizily Scott | other | 1,635 |
| Sep 16, 26 | Bizily Scott | sell | 1,635 |
| Sep 14, 26 | Kirn David | sell | 58,333 |
| Sep 1, 26 | Bizily Scott | other | 584 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FDMT coverage
Recent articles, reports, and earnings notes.
No research on FDMT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FDMT report →4D Molecular Therapeutics, Inc. (FDMT) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 13
4DMT Announces New Employment Inducement Grants
globenewswire.com · Nov 13
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 12
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
globenewswire.com · Nov 12
4D Molecular Therapeutics, Inc. (FDMT) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
seekingalpha.com · Nov 11
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Now Rated “Moderate Buy” by Wall Street Brokerages
defenseworld.net · Nov 7
4DMT to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 3
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.